Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 145

1.

Identification of quaternary ammonium compounds as potent inhibitors of hERG potassium channels.

Xia M, Shahane SA, Huang R, Titus SA, Shum E, Zhao Y, Southall N, Zheng W, Witt KL, Tice RR, Austin CP.

Toxicol Appl Pharmacol. 2011 May 1;252(3):250-8. doi: 10.1016/j.taap.2011.02.016. Epub 2011 Feb 26.

2.

A new homogeneous high-throughput screening assay for profiling compound activity on the human ether-a-go-go-related gene channel.

Titus SA, Beacham D, Shahane SA, Southall N, Xia M, Huang R, Hooten E, Zhao Y, Shou L, Austin CP, Zheng W.

Anal Biochem. 2009 Nov 1;394(1):30-8. doi: 10.1016/j.ab.2009.07.003. Epub 2009 Jul 5.

3.

Mechanism of HERG potassium channel inhibition by tetra-n-octylammonium bromide and benzethonium chloride.

Long Y, Lin Z, Xia M, Zheng W, Li Z.

Toxicol Appl Pharmacol. 2013 Mar 1;267(2):155-66. doi: 10.1016/j.taap.2012.12.021. Epub 2013 Jan 8.

4.

Identification of human Ether-à-go-go related gene modulators by three screening platforms in an academic drug-discovery setting.

Huang XP, Mangano T, Hufeisen S, Setola V, Roth BL.

Assay Drug Dev Technol. 2010 Dec;8(6):727-42. doi: 10.1089/adt.2010.0331.

5.

A pharmacologically validated, high-capacity, functional thallium flux assay for the human Ether-à-go-go related gene potassium channel.

Schmalhofer WA, Swensen AM, Thomas BS, Felix JP, Haedo RJ, Solly K, Kiss L, Kaczorowski GJ, Garcia ML.

Assay Drug Dev Technol. 2010 Dec;8(6):714-26. doi: 10.1089/adt.2010.0351.

PMID:
21158686
6.

Inhibition of HERG potassium channels by domiphen bromide and didecyl dimethylammonium bromide.

Long Y, Chen W, Lin Z, Sun H, Xia M, Zheng W, Li Z.

Eur J Pharmacol. 2014 Aug 15;737:202-9. doi: 10.1016/j.ejphar.2014.05.002. Epub 2014 May 15.

7.

The binding site for channel blockers that rescue misprocessed human long QT syndrome type 2 ether-a-gogo-related gene (HERG) mutations.

Ficker E, Obejero-Paz CA, Zhao S, Brown AM.

J Biol Chem. 2002 Feb 15;277(7):4989-98. Epub 2001 Dec 10.

8.

Automated electrophysiology in the preclinical evaluation of drugs for potential QT prolongation.

Guo L, Guthrie H.

J Pharmacol Toxicol Methods. 2005 Jul-Aug;52(1):123-35.

PMID:
15936217
9.

Identification and characterization of a compound that protects cardiac tissue from human Ether-à-go-go-related gene (hERG)-related drug-induced arrhythmias.

Potet F, Lorinc AN, Chaigne S, Hopkins CR, Venkataraman R, Stepanovic SZ, Lewis LM, Days E, Sidorov VY, Engers DW, Zou B, Afshartous D, George AL Jr, Campbell CM, Balser JR, Li M, Baudenbacher FJ, Lindsley CW, Weaver CD, Kupershmidt S.

J Biol Chem. 2012 Nov 16;287(47):39613-25. doi: 10.1074/jbc.M112.380162. Epub 2012 Oct 2.

10.

Comparison of human Ether-à-go-go related gene screening assays based on IonWorks Quattro and thallium flux.

Bridal TR, Margulis M, Wang X, Donio M, Sorota S.

Assay Drug Dev Technol. 2010 Dec;8(6):755-65. doi: 10.1089/adt.2010.0267. Epub 2010 Jul 26.

PMID:
20658944
11.

Human embryonic stem cell derived cardiac myocytes detect hERG-mediated repolarization effects, but not Nav1.5 induced depolarization delay.

Qu Y, Gao B, Fang M, Vargas HM.

J Pharmacol Toxicol Methods. 2013 Jul-Aug;68(1):74-81. doi: 10.1016/j.vascn.2013.03.001. Epub 2013 Mar 19.

PMID:
23518063
12.

Propofol inhibits hERG K+ channels and enhances the inhibition effects on its mutations in HEK293 cells.

Han SN, Jing Y, Yang LL, Zhang Z, Zhang LR.

Eur J Pharmacol. 2016 Nov 15;791:168-178. doi: 10.1016/j.ejphar.2016.08.028. Epub 2016 Aug 26.

PMID:
27575519
13.

Clemastine, a conventional antihistamine, is a high potency inhibitor of the HERG K+ channel.

Ridley JM, Milnes JT, Hancox JC, Witchel HJ.

J Mol Cell Cardiol. 2006 Jan;40(1):107-18. Epub 2005 Nov 9.

PMID:
16288909
14.

hERG channel blockade by externally applied quaternary ammonium derivatives.

Choi KH, Song C, Shin D, Park S.

Biochim Biophys Acta. 2011 Jun;1808(6):1560-6. doi: 10.1016/j.bbamem.2011.02.008. Epub 2011 Feb 12.

15.

Effect of azelastine on cardiac repolarization of guinea-pig cardiomyocytes, hERG K⁺ channel, and human L-type and T-type Ca²⁺ channel.

Park MH, Lee SH, Chu DH, Won KH, Choi BH, Choe H, Jo SH.

J Pharmacol Sci. 2013 Sep 20;123(1):67-77. Epub 2013 Sep 3.

16.
17.

Cardiac glycosides as novel inhibitors of human ether-a-go-go-related gene channel trafficking.

Wang L, Wible BA, Wan X, Ficker E.

J Pharmacol Exp Ther. 2007 Feb;320(2):525-34. Epub 2006 Nov 9.

18.

Investigating dynamic protocol-dependence of hERG potassium channel inhibition at 37 degrees C: Cisapride versus dofetilide.

Milnes JT, Witchel HJ, Leaney JL, Leishman DJ, Hancox JC.

J Pharmacol Toxicol Methods. 2010 Mar-Apr;61(2):178-91. doi: 10.1016/j.vascn.2010.02.007. Epub 2010 Feb 19.

PMID:
20172036
19.

Comparative pharmacology of guinea pig cardiac myocyte and cloned hERG (I(Kr)) channel.

Davie C, Pierre-Valentin J, Pollard C, Standen N, Mitcheson J, Alexander P, Thong B.

J Cardiovasc Electrophysiol. 2004 Nov;15(11):1302-9.

PMID:
15574182
20.

The anti-malarial drug halofantrine and its metabolite N-desbutylhalofantrine block HERG potassium channels.

Mbai M, Rajamani S, January CT.

Cardiovasc Res. 2002 Sep;55(4):799-805.

PMID:
12176129

Supplemental Content

Support Center